After cardiovascular disorders, cancer is the world 's second leading cause of mortality. The location of the cancer in the bodily organ determines the type of cancer. Different forms of cancer have different metabolic behaviors that are sometimes conflicting. Nonetheless, the oncogenic phenotype is supported by each cancer's unique metabolism. The immuno-biological microenvironments at distinct metastatic organ sites are major factors for variances in efficacy, and immunotherapy benefits a small proportion of patients across multiple cancer types. Recent advancements in cancer diagnosis and treatment, cancer survival has increased, and so there is a greater emphasis on quality rather than quantity of survival.
Important Alert:
X
Title : Deubiquitylase USP31 induces autophagy and promotes the progression in lung squamous cell carcinoma cells by stabilizing E2F1 expression
Qian Zhang, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, China
Title :
Luca Roncati, University of Modena and Reggio Emilia, Italy
Title :
Bene Ekine-Afolabi, ZEAB Therapeutic Ltd, United Kingdom
Title :
K.P.Mishra, Asian Association for Radiation Research, India